Stock listing

OTC:PBLA Panbela Therapeutics, Inc. Stock

Follow Panbela Therapeutics, Inc. into a list and get an email when it puts out news.

Share price · OTC:PBLA

$0.011 USD 0.000 (0.0%)

Close on Oct 30, 2026

Past year 0.0% · daily closes, Oct 26, 2026 – Oct 30, 2026, adjusted for splits

Day range: $0.011 – $0.011 USDOct 30, 2026
Market cap: $53,889 USDAt the close on Oct 30, 2026 · price × 4.85M shares outstanding

Daily closes

Last 3 months, Oct 26, 2026 – Oct 30, 2026 · OTC:PBLA · USD, adjusted for splits

Day	Close	Change	%	Open	High	Low	Volume
Fri, Oct 30	$0.011	0.000	0.0%	$0.011	$0.011	$0.011	0
Thu, Oct 29	$0.011	0.000	0.0%	$0.011	$0.011	$0.011	0
Wed, Oct 28	$0.011	0.000	0.0%	$0.011	$0.011	$0.011	0
Tue, Oct 27	$0.011	0.000	0.0%	$0.011	$0.011	$0.011	0
Mon, Oct 26	$0.011	—	—	$0.011	$0.011	$0.011	112

Ticker: OTC:PBLA
Asset type: Stock
Sector: Health care
Industry: Biotechnology
Exchange: OTC
Currency: USD

Calls

Replays

Panbela Therapeutics (OTC:PBLA) Q3 2024 Earnings Call
Thu, Nov 14, 2024 · 4:30 PM ET
Watch Transcript
Panbela Therapeutics (OTC:PBLA) Q2 2024 Earnings Call
Tue, Aug 13, 2024 · 4:30 PM ET
Watch Transcript
Panbela Therapeutics (OTC:PBLA) Q1 2024 Earnings Call
Wed, May 15, 2024 · 4:30 PM ET
Watch Transcript

Latest news

Panbela Provides Business Update and Reports Q3 2024 Financial Results

Nov 14, 2024

Panbela to Host Third Quarter 2024 Earnings Conference Call on November 14, 2024

Oct 31, 2024

First Patient Enrolled in Phase I Program in STK11 Mutant Non-Small Cell Lung Cancer at Moffitt Cancer Center

Sep 24, 2024

Panbela Provides Business Update and Reports Q2 2024 Financial Results

Aug 13, 2024

Panbela to Host Second Quarter 2024 Earnings Conference Call on Aug 13, 2024

Jul 30, 2024

Panbela Therapeutics Announces Third Independent Safety Review of Phase 3 ASPIRE Clinical Trial DSMB Recommended Continuation with No Trial Modification

Jun 24, 2024

Panbela Announces Oral Presentation at Digestive Disease Week (DDW):

Jun 10, 2024

Panbela Provides Business Update and Reports Q1 2024 Financial Results

May 15, 2024

Panbela Announces Issuance of New Patent in the US and Canada; Patent is for Claims of a Fixed Dose Combination of Eflornithine and Sulindac

May 6, 2024

Panbela to Host First Quarter 2024 Earnings Conference Call on May 15, 2024

May 1, 2024

All Panbela Therapeutics, Inc. news

Decks

Investor Presentation (August 2023)
Investor deck · 38 slides · Aug 17, 2023
Investor Presentation (July 2023)
Investor deck · 38 slides · Jul 10, 2023
Investor Presentation (March 2023)
Investor deck · 39 slides · Mar 9, 2023
Investor Presentation (September 2022)
Investor deck · 37 slides · September 2022

Panbela Therapeutics, Inc. on 6ix

Sector: Health care
Industry: Biotechnology
News releases: 54 in all · newest Nov 14, 2024 · oldest 2016
Calls: 13 calls with a replay · 13 with a transcript · latest Nov 14, 2024
Decks: 8 decks · latest Aug 17, 2023

Log in to ask 6ix AI your own questions about Panbela Therapeutics, Inc.